Chime Biologics Launches Innovative Commercial CDMO Ecosystem Platform on 10th Anniversary with Integrated Financing, Talent, and Business Development Support

Following its pioneering introduction of KUBio, the world’s first modular biopharmaceutical manufacturing facility, Chime Biologics, a large-molecule biologics CDMO, has announced new developments.

On May 19, Chime Biologics held its 10th-anniversary celebration, themed “A Decade, A New Voyage,” at its Wuhan headquarters.The conference saw the major unveiling of its new business model—the CDMO Business Ecosystem Platform.

CDMOs have emerged as a hot trend in China’s pharmaceutical services and supply chain sector in recent years. An increasing number of CROs are actively transitioning toward the CDMO model, while manufacturers of biosimilars and pharmaceutical companies are also gearing up to enter the market. The CDMO landscape is becoming increasingly crowded.

Against the broader backdrop of the pharmaceutical industry, the rise of CDMOs in recent years is by no means without precedent. Since 2022, China’s pharmaceutical sector has been experiencing a “capital winter,” with investors adopting a wait-and-see approach and liquidity in the market declining. In response, biotech companies have had no choice but to conserve their cash reserves and opt for R&D pathways that are lower in cost and risk. CDMOs, which offer outsourced R&D and manufacturing services, have thus become a popular choice.

How to Stand Out in China’s CDMO Sector: Chime Biologics Chooses to Build a New Commercial Ecosystem Platform. “The risks and interests of biotech companies and CDMOs are entirely different. However, to make biotech companies feel that we can address their pain points, our business model must change,” said Wei Jianzhong, President of Chime Biologics.“The core of our business lies in understanding the pain points of each pharmaceutical enterprise. Under the new pricing model, we no longer charge simply on a per-order basis; instead, we share risks with biotech companies.”

Dr. Wei Jianzhong introduced that this ecosystem will provide pharmaceutical companies with venture capital funds supporting corporate management and commercialization, a global business development (BD) platform, and talent resources, as well as a drug discovery platform, a Good Laboratory Practice (GLP) animal testing platform, biologics contract development and manufacturing organization (CDMO) services, clinical trial platforms, and government regulatory resources to support pipeline research and development.

The event comprises two main segments: a celebration ceremony and a forum.

At the start of the event,Li Shiting, Chief Engineer of the Administrative Committee of East Lake High-Tech Development Zone, WuhanInvited to deliver a promotional presentation for the Optics Valley Bio-City in Donghu District.Dan Changchun, Deputy Director of the Standing Committee of the 14th Wuhan Municipal People’s Congress, Deputy Head and Director of the Office of the Wuhan Leading Group for the Big Health and Biotechnology Industry; Yan Zhongning, Member of the Decision-Making Advisory Committee of the Wuhan Municipal People’s GovernmentTwelve guests, including [Name], participated in the launch ceremony of the celebration.

Li Shiting, Chief Engineer of the Administrative Committee of East Lake High-Tech Development Zone, Wuhan City

Huang Ruijin, Chairman of Chime Biologics, stated in his address: “The achievements of the past decade have been hard-won. As a witness to Chime’s ten-year journey, I feel a profound sense of pride.”We extend our sincere gratitude to the Hubei Provincial Government, Wuhan Municipal Government, East Lake High-Tech Development Zone, and the Biological Industry Office, as well as leaders at all levels, for their care and strong support. We also thank our industry peers for their trust and support, and every member of Chime Biologics for their perseverance, professionalism, and dedication. Thank you for upholding the belief in achieving success for both the company and our customers, enabling Chime Biologics to reach one milestone after another.” 

Huang Ruijin, Chairman of Chime Biologics

Mr. Zhuang Tianlong, Chairman of Dingpei Group, stated: “Congratulations to Chime Biologics on its 10th anniversary. Chime Biologics is the most important investment project for our Dingpei.“In 2019, after evaluating several CDMO companies similar to Chime Biologics, we were particularly impressed by Chime’s technological advantages and talent pool, and ultimately chose to invest in the company and facilitate its transformation. Importantly, the company places a strong emphasis on high-quality standards. As the largest shareholder of Chime Biologics, together with our strategic investor, Chow Tai Fook Group from Hong Kong, the Dingpei Group is highly confident in the future development of Chime Biologics.”

 Zhuang Tianlong, Chairman of Dingpei Group

Dr. Wei Jianzhong, President of Chime Biologics, unveiled the company’s “New Business Model” on its behalf. Dr. Wei Jianzhong stated, “Chime Biologics is building a more meaningful commercial ecosystem platform to share risks and grow together with its customers. Its comprehensive biologics solutions are set for further enhancement: “Give us an idea, whether it be a sequence or the brand name of a biosimilar, and we will deliver the product.””

Dr. Wei Jianzhong, President of Chime Biologics

Hu Chaohong, Executive Director and Co-General Manager of Lepu Biopharma; Xiao Ruiping, Dean of the School of Future Technology at Peking University, Deputy Editor-in-Chief of The New England Journal of Medicine, and Founder and Chairman of Herui Pharma; delivered keynote speeches on the topics of “Current Status and Opportunities in ADC Drug Development” and “NEJM and Clinical Research and Drug R&D in China,” respectively.

Hu Chaohong, Executive Director and Co-General Manager of Lepu Biopharma

Xiao Ruiping, Dean of the School of Future Technology at Peking University, Deputy Editor-in-Chief of The New England Journal of Medicine, and Founder and Chairman of Heqirui

The conference also held“How Will China’s Pharmaceutical Industry Evolve in the Next Decade,” “How Chinese Pharmaceutical Companies Will Navigate Through the Capital Winter”Themed Roundtable Forum.

More than ten entrepreneurs, scientists, and investors from innovative pharmaceutical companies—including Su Weiguo, Executive Director, CEO, and Chief Scientific Officer of Hutchmed; Wang Jinsong, Chairman and CEO of Harbour Biomed; Li Xiaoyi, Chairman of the Board of Zai Lab Ophthalmics (Zhaoke Eye Care); Zhou Pengfei, Chairman and CEO of YZY Biopharma; Luo Peizhi, CEO of Allist Pharmaceuticals; Zhou Chao, CEO of Grand Pharma; and Wu Zhaowei, Head of Healthcare Investment at Dingsui Group—discussed key industry issues, including the innovative future of China’s pharmaceutical sector, trends in pharmaceutical innovation and development, and strategies to address financing challenges faced by innovative drug companies.

“Walking this journey together, we are grateful for the trust and support of our partners and industry peers, who have witnessed our growth.” Wei Jianzhong, President of Chime Biologics, stated, “Over the past decade, Chime Biologics has upheld the pioneering entrepreneurial spirit of blazing new trails, leveraging its comprehensive biologics manufacturing capabilities and internationally recognized expertise to provide holistic, end-to-end solutions for global biopharmaceutical clients.Going forward, the new business model will empower more partners to share risks and achieve mutual growth, with the aim of establishing Wuhan as a global hub for biopharmaceutical R&D and manufacturing.”

Over the next decade, Chime Biologics aims to strengthen ecosystem integration with a more proactive and enterprising approach, continuously expand its global market presence, and drive the rapid development of the pharmaceutical industry.

Chime Biologics is a leading CDMO that pioneered the introduction of KUBio, the world’s first modular biopharmaceutical manufacturing facility, empowering the entire biologic product lifecycle from cell line development to commercial manufacturing. Currently, Chime Biologics integrates its Shanghai Innovation Center, which focuses on high-efficiency cell line development and advanced technology innovation, with its Wuhan manufacturing site, which boasts extensive experience in securing clinical trial approvals and achieving successful new drug launches across multiple countries. This synergy enables the company to provide one-stop CMC solutions for global biopharmaceutical clients. Committed to improving patient access to cutting-edge biomedicines worldwide, Chime Biologics upholds its dedication to human health.